Earnings ·
Zoetis Inc. reported second quarter 2026 financial results on August 6, 2026, revealing flat revenue of $2.47 billion…
ZTSZoetis Inc.
Zoetis Inc. reported second quarter 2026 financial results on August 6, 2026, revealing flat revenue of $2.47 billion and net income of $691 million, or $1.65 per diluted share. Adjusted net income was $781 million, or $1.87 per diluted share. The company cited pressured demand in the Companion Animal market due to lower clinic visits and price sensitivity, which drove a 7% decline in U.S. segment revenue. Conversely, International revenue grew 6% organically, supported by new product launches like Lenivia and Portela. Zoetis revised its full year 2026 guidance downward, lowering organic operational revenue growth expectations to (3)% to (1)% and adjusted diluted EPS to $6.15 - $6.25. The company also announced the acquisition of VitalRADS to expand its diagnostics capabilities. Zoetis operates in the animal health industry, developing and commercializing medicines, vaccines, and diagnostics for companion animals and livestock.